Do You Regain Weight After Stopping GLP-1 Drugs?
Published Jul 2, 2026 · Updated Sep 12, 2026 · 5 minute read
It is one of the most important and most searched questions about GLP-1 medicines: what happens when you stop? The research has a fairly clear answer, and understanding it reframes how these drugs are thought about, from a quick fix to a chronic-condition treatment.
Key Takeaways
- Research consistently shows weight tends to return after stopping GLP-1 medicines.
- In the STEP 1 extension, participants regained about two-thirds of lost weight within a year of stopping semaglutide.
- This reflects how obesity is managed as a chronic condition, not a personal failure.
- When the drug stops, the appetite and metabolic effects that drove the loss fade.
- Whether, when, and how to start or stop is a clinical decision, not one this page advises on.
- This page is educational and is not medical advice.
1. The Short Answer
Research consistently shows that weight tends to return after stopping GLP-1 medicines. The most cited evidence comes from the extension of the STEP 1 trial of semaglutide: about a year after stopping, participants had regained roughly two-thirds of the weight they had lost.
This is a study average, and individual experiences vary, but the overall pattern, regain after discontinuation, has been seen across multiple studies and drugs.
2. Why the Weight Comes Back
GLP-1 medicines work while they are being taken. They reduce appetite and affect metabolic signals, which drives the weight loss. When the medication stops, those effects fade, and the body’s underlying appetite and weight-regulation systems reassert themselves.
In other words, the drug does not permanently reset the body’s set point; it manages it during treatment. That is why stopping tends to be followed by regain.
3. The Chronic-Condition Framing
This finding has shifted how clinicians and researchers talk about obesity treatment. Rather than a short course that produces a permanent result, GLP-1 therapy is increasingly framed like treatment for other chronic conditions, such as high blood pressure, where the benefit depends on ongoing management.
| Mental model | Implication |
|---|---|
| Short-term fix | Expect lasting results after stopping |
| Chronic-condition management | Effect depends on continued treatment |
The research supports the second framing, and it is not a statement about willpower; regain reflects physiology.
4. What the Numbers Mean (and Don’t)
Tirzepatide now has its own withdrawal trial, so the two molecules can be set side by side.
| Trial | Design | Weight change on drug | After switching to placebo | Staying on drug |
|---|---|---|---|---|
| STEP 1 extension | Semaglutide 2.4 mg for 68 weeks, then all treatment stopped, followed 52 weeks | −17.3% at week 68 | Regained about two-thirds of the loss by week 120 | Not tested |
| SURMOUNT-4 | Tirzepatide for 36 weeks, then randomised to continue or switch to placebo for 52 weeks | −20.9% at week 36 | +14.0% from week 36 to 88; only 16.6% kept at least 80% of their loss | −5.5% further; 89.5% kept at least 80% of their loss |
The pattern is the same for both molecules. Stop the drug and most of the weight returns within a year; continue it and the loss holds or extends. The “about two-thirds regained” figure is useful but should be read carefully:
- It is a trial-population average, not a personal prediction.
- It came from a specific study (the STEP 1 extension) with its own design and population.
- Individual outcomes depend on many factors beyond the drug alone.
Cross-study and individual variation are real, so treat the number as a representative finding, not a fixed rule.
5. The Bottom Line
- Regain is common after stopping GLP-1 medicines.
- About two-thirds of lost weight returned within a year in the STEP 1 extension, and tirzepatide showed the same pattern in SURMOUNT-4.
- This reflects physiology and the chronic nature of obesity, not failure.
- Starting and stopping decisions belong with a qualified clinician.
7. Weight Regain After Stopping GLP-1 FAQ
Do you gain the weight back after stopping Ozempic or Wegovy?
Research suggests most people regain a substantial portion of the weight after stopping GLP-1 medicines. In the STEP 1 extension study, participants regained about two-thirds of the weight they had lost within roughly a year of stopping semaglutide. Individual results vary, and this is not medical advice.
Why does weight come back after stopping?
GLP-1 medicines work while they are being taken, reducing appetite and affecting metabolism. When the drug is stopped, those effects fade, and the body's underlying appetite and weight-regulation signals reassert themselves. This is why obesity is often described as a chronic condition.
How much weight is typically regained?
Figures vary by study and person. The most cited number comes from the STEP 1 extension, where about two-thirds of lost weight returned within about a year of stopping. That is a study average, not a guarantee for any individual.
Does this mean GLP-1 drugs do not work?
No. It means their effect depends on ongoing use, similar to many medications for chronic conditions like blood pressure. The weight loss is real while taking the drug; the regain reflects stopping it. This page does not advise on starting or stopping anything.
Should I stop my GLP-1 medication?
That is a decision for you and a qualified prescriber, based on your situation. This page explains what research shows about regain; it does not recommend starting, continuing, or stopping any medication.
8. Sources
References used for this article
- Wilding et al., Diabetes Obes Metab 2022: STEP 1 extension (weight regain after withdrawal)
- Wilding et al., NEJM 2021: STEP 1 semaglutide trial
- NIH / NIDDK: Treatment for overweight and obesity
- Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 2024;331:38-48.